Neuberger Berman Group
BMRN icon

Neuberger Berman Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Neuberger Berman Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,899
Closed -$957K – 2058
2025
Q1 		$957K Buy
2,899
+675
+30% +$45.4K ﹤0.01% 1330
2024
Q4 		$662K Buy
+2,224
New +$149K ﹤0.01% 1441

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group's BMRN Position: Q1 2026 in Review

Neuberger Berman Group increased its BioMarin Pharmaceuticals (BMRN) stake by 0.95% in Q1 2026, buying an estimated $20.5K and bringing the position to 37,469 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Neuberger Berman Group first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $126M in Q3 2018. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Neuberger Berman Group held 37,469 shares of BioMarin Pharmaceuticals worth $2.12M as of Q1 2026.
  • Neuberger Berman Group bought 352 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $20.5K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1167 holding.
  • Neuberger Berman Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Neuberger Berman Group's BioMarin Pharmaceuticals position peaked at $126M in Q3 2018.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.